Keyphrases
Dengue Vaccine
55%
Highly Active Antiretroviral Therapy (HAART)
50%
Dengue
45%
TV003
41%
Live Attenuated Tetravalent Dengue Vaccine
38%
Dengue Virus
32%
Tetravalent
30%
Rash
29%
Neutralizing Antibodies
28%
Immunogenicity
27%
Infectious Diseases
25%
Live Attenuated
25%
Viremia
23%
Vaccination
23%
Second Dose
22%
Flavivirus
20%
Allergy Disease
20%
Human Immunodeficiency Virus Infection
19%
Human Challenge Model
19%
DENV-2
19%
Dengue Virus Serotype 2
19%
Tetravalent Vaccine
18%
Hepatitis A Virus
16%
Early HIV Infection
16%
Immune Activation
16%
Urine Antibody
16%
Immune Response
16%
Early Humans
16%
Positron Emission Tomography
16%
Attenuation Correction
16%
Standardized Uptake Value
16%
Randomized Clinical Trial
16%
Tetravalent Dengue Vaccine
16%
IL-12 Production
16%
Attenuation
16%
Therapy Modification
16%
Clinical Significance
16%
Recombinant
16%
Filtered Back Projection
16%
Fluorodeoxyglucose
16%
Complete Protection
16%
Iterative Reconstruction
16%
Resting CD4+ T Cells
16%
Non-associated
16%
Virus Genome
16%
Local Inflammation
16%
Skin Rash
16%
Live Attenuated Tetravalent
14%
Placebo
14%
Vaccinees
13%
Pharmacology, Toxicology and Pharmaceutical Science
Dengue Vaccine
100%
Infection
79%
Dengue
58%
Placebo
44%
Viremia
37%
Flavivirus
37%
Neutralizing Antibody
36%
Dengue Virus
31%
Immunogenicity
29%
Vaccination Policy
26%
Rash
26%
Dengue Virus 2
23%
Dengue Virus 4
20%
Clinical Trial
20%
Disease
19%
Human Immunodeficiency Virus 1
16%
Atherosclerosis
16%
Hepatitis A Virus
16%
Human Immunodeficiency Virus Infection
16%
Randomized Clinical Trial
16%
Dosing Studies
16%
Vaccine
13%
Adverse Event
12%
Neutropenia
11%
Controlled Clinical Trial
8%
Dengue Virus 3
8%
HIV
8%
Aluminum Hydroxide
8%
Normal Human
5%
Immunology and Microbiology
Dengue Vaccine
66%
Viremia
41%
Human Immunodeficiency Virus 1
39%
Serotype
38%
Human Immunodeficiency Virus
37%
Human Immunodeficiency Virus Infection
33%
Dengue Fever
33%
Dengue Virus
33%
Vaccine Efficacy
31%
Dengue Virus 2
26%
Neutralizing Antibody
20%
Antibody Response
20%
T Cell
20%
Immune Response
19%
Viral Load
19%
T-Helper Cell
18%
Hepatitis A Virus
16%
Flavivirus
16%
Dengue Virus 4
16%
Atherosclerosis
16%
Infectious Disease
16%
Positron Emission Tomography
16%
Virus Genome
16%
Vaccination Policy
11%
Dengue Virus 3
8%
Immunogenicity
8%
Prevalence
8%
Viral Replication
7%
Multiple Drug Dose
5%
Normal Human
5%
In Situ Hybridization
5%
Dermatitis
5%
Virus Strain
5%
Lymphocyte
5%